Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
Standard metrics generated by continuous glucose monitors (CGM), such as average glucose, time-in-range (TIR), and the glycemic management indicator (GMI), may not align with A1c in people who don’t ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom received FDA clearance for a 15-day version of its G7 continuous glucose monitor. (Courtesy of Dexcom) This story was ...
A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that ...
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
NEW ORLEANS — In adults with type 2 diabetes (T2D) who are not treated with insulin, continuous glucose monitoring (CGM) provided substantial improvements in hyperglycemia compared with those ...
The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...
New data from Dexcom has demonstrated the benefit of its G7 continuous glucose monitor (CGM) in type 2 diabetes (TD2) patients not receiving insulin, suggesting a new standard of care (SoC) could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results